Abstract
Understanding the disease-level patient experience is increasingly important to HTA and regulatory agencies when evaluating new therapies. Disease-level patient experience expands on evidence collected in clinical trials, covering areas including unmet need in the disease state and patient preferences. This review compared the role and usage of disease-level patient experience across several HTA bodies and regulatory agencies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
